cell carcinoma at a late stage of autoimmune liver disease. These studies suggest that integration of the HBV genome occurs rarely or in only a small proportion of hepatocytes during the early (HBe antigen positive) phase of infection in Caucasians. They also show that not all primary liver cell carcinomas necessarily contain HBV-DNA.
The epidemiological evidence suggesting that hepatitis B virus (HBV) is an aetiological agent for primary liver cell carcinoma is strong.' 2 There is a positive correlation between the geographic prevalence of chronic HBV infection and that of primary liver cell carcinoma,3 4 multiple studies show an excess incidence of HBs antigen positivity in primary liver cell carcinoma cases compared with normal individuals and patients with other tumours, 7 and a prospective study in Taiwan has shown that HBs antigen positive individuals are 390 times more likely to develop primary liver cell carcinoma than HBs antigen negative subjects. 8 Following the cloning of HBV-DNA, molecular hybridisation techniques were used to study the relationship of the viral DNA to the host genome. Initially several groups examined the Alexander primary liver cell carcinoma cell line,911 and subjects was the presence of HBV-DNA integrated into the host genome. In rare cases episomal HBV-DNA was present. 14 These studies were initially interpreted as evidence of direct oncogenic potential of the virus. Subsequently, tissues from chronically infected patients without evidence of malignant disease were studied and a variable prevalence of integration was found. 15 Thus it became apparent that integration of HBV-DNA into the hepatocyte genome preceded development of primary liver cell carcinoma.
In the present study we have examined serum and liver tissue from patients with HBe antigen and antibody positive chronic HBV infection for the presence of, and molecular state of, HBV-DNA sequences. These data provide insight into the sequence of molecular events occurring during conversion from HBe antigenaemia to the phase of anti-HBe production when it occurs spontaneously and during therapy with adenine arabinoside mono- Figure 1A were artefacts which were not present on further filters prepared from this patient's liver DNA.
(b) HBe antibody positive patients (Figs. 2 and 3 ) Seven patients with chronic liver disease, without liver tumours were examined. Six were negative for HBV-DNA in serum. In the remaining patient (No. 16 in Table) who was HBV-DNA polymerase positive, HBV-DNA was present in the serum in the form of a 2-8 to 2-0 Kb smear (Fig. 2, lane b) .
Free HBV-DNA was not detected in liver tissue from all six patients who were also HBV-DNA and HBV-DNA polymerase negative in serum. The results for five of these patients (No. 17-21) are shown in Fig. 3 lanes a-e. In patient 16, who was positive for HBV-DNA in serum, free HBV-DNA was also present in the liver (Fig. 2, lane a) . In three patients (No. 17, 18 and 19), HBV-DNA sequences were found in high molecular weight DNA after Hind III digestion (Fig. 3, lanes a, b and c) . Of these three patients, one is Spanish and the other two Middle Eastern.
(c) HBe antigen to antibody seroconversion (Fig. 4) . The pattern of HBV-DNA in the serum in three HBe antigen positive patients (No. 23-25) before treatment with ARA-A monophosphate was similar to that seen in the other HBe antigen positive patients (Fig. 1B) . There was no 3.2 Kb band visible at this stage. After four weeks of therapy, HBV-DNA was either weakly detectable or absent. On stopping treatment HBV-DNA polymerase became transiently positive and towards the end of this stage a 3-2 Kb band of HBV-DNA was seen either alone or in association with a faint 2-8 to 2-0 Kb smear. Finally, HBV-DNA disappeared and HBe antibody appeared. This sequence of events was seen in all three patients (Fig. 4, lanes a, b and c) . For patients 24 and 25 (Fig. 4 lanes b and c) the DNA negative tracks post treatment were omitted. In every case HBV-DNA in serum has remained negative in subsequent follow-up.
PRIMARY LIVER CELL CARCINOMA Two of the four liver cell carcinomas contained HBV-DNA sequences in the high molecular weight DNA (Fig. 5, lanes a and b) . In the two that were initially negative, the DNA load on the gel was a b c d. normal, free HBV-DNA disappeared both from the serum and liver. Whether the serum 3*2 Kb band is a replicative intermediate transiently released into the serum during elimination of HBV replicating cells or is a reflection of the liver's ability to produce virus particles with a complete plus strand during low but not high level replication, remains to be determined. Four patients with primary liver cell carcinoma were studied. All four were HBs antigen negative by radioimmunoassay but two were positive for antiHBc in the absence of anti-HBs. These two patients had integrated HBV-DNA sequences in their liver tissue whereas the two without serological markers of HBV infection were negative for HBV-DNA. The latter patients had autoimmune liver diseases (primary biliary cirrhosis and lupoid chronic active hepatitis) and had been treated with prednisolone and azathioprine. In these it seems improbable that HBV had a role and more likely that an immune defect underlay the development of the tumours.26
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